Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - nortriptyline hydrochloride - film-coated tablet - 25 milligram(s) - non-selective monoamine reuptake inhibitors; nortriptyline

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - probenecid, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; stearic acid; magnesium stearate; maize starch; microcrystalline cellulose; povidone; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; sunset yellow fcf; quinoline yellow; polysorbate 80 - indications as at 25 may 2000 : gout - probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except an acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and smiliar diuretics). b-lactam antibiotic therapy - probenecid is indicated for the elevation and prolongation of plasma levels by whatever route the antibiotic is given. a two-to-fourfold increase in plasma levels has been demonstrated for benzylpenicillin, phenoxymethylpenicillin, the synthetic penicillins, ampicillin, methicillin, oxacillin, cloxacillin, nafcillin, carbenicillin, and for the cephamycin, mefox

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 10 mg; doxylamine succinate, quantity: 5.1 mg - tablet, uncoated - excipient ingredients: crospovidone; lactose monohydrate; stearic acid; magnesium stearate; maize starch; ethanol; povidone; microcrystalline cellulose - for the temporary relief of acute moderate pain and fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 9.6 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; magnesium stearate; purified talc; stearic acid; povidone; pregelatinised maize starch; crospovidone - for the relief of acute moderate pain and fever

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 9.75 mg; doxylamine succinate, quantity: 5 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; sodium starch glycollate; quinoline yellow; sunset yellow fcf; stearic acid; povidone; pregelatinised maize starch; crospovidone - for the relief of acute moderate pain and fever

Canada - English - Health Canada

sanofi-aventis canada inc - codeine phosphate; doxylamine succinate; acetaminophen - tablet - 8mg; 5mg; 325mg - codeine phosphate 8mg; doxylamine succinate 5mg; acetaminophen 325mg - opiate agonists

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - doxylamine succinate, quantity: 5 mg; codeine phosphate hemihydrate, quantity: 9.75 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: quinoline yellow; sodium starch glycollate; sunset yellow fcf; purified talc; magnesium stearate; microcrystalline cellulose; stearic acid; povidone; pregelatinised maize starch; crospovidone - for the relief of acute moderate pain and fever

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - nortriptyline hydrochloride - film-coated tablet - 10 milligram(s) - non-selective monoamine reuptake inhibitors; nortriptyline